LYTIX — Lytix Biopharma AS Income Statement
0.000.00%
Last trade - 00:00- NOK696.27m
- NOK608.70m
- NOK11.13m
Annual income statement for Lytix Biopharma AS, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | NAS | NAS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.003 | 19.3 | 11 | 3.99 | 11.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 42.4 | 67.3 | 76.7 | 101 | 107 |
| Operating Profit | -42.4 | -48 | -65.7 | -96.8 | -95.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -42.1 | -48.1 | -56.1 | -87.9 | -94.3 |
| Net Income After Taxes | -42.1 | -48.1 | -56.1 | -87.9 | -94.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -42.1 | -48.1 | -56.1 | -87.9 | -94.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -42.1 | -48.1 | -56.1 | -87.9 | -94.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.07 | -1.43 | -1.39 | -2.16 | -1.74 |
| Dividends per Share |